Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Hemolytic Uremic Syndrome

In brief

OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome. II. Determine the effect of SYNSORB Pk therapy on the need for the duration of dialysis in these patients. III. Determine the effect of SYNSORB Pk therapy on the recovery of renal function and resolution of urinary abnormalities in these patients.

Key facts

Study ID
NCT00004465
Run by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
People needed
145
Starts
1997-07-27
Expected to finish
2001-04-14
Last updated by the study team
2017-06-01

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.